Sentences with phrase «lymphoma patients»
The phrase "lymphoma patients" refers to people who have been diagnosed with lymphoma, which is a type of cancer that affects the lymphatic system. Full definition
The researchers also studied samples taken from lymphoma patients.
sciencedaily.com
Often, the canine lymphoma patient comes to the veterinarian because one or more lumps have been found.
Most lymphoma patients don't experience a lot of overt pain, especially early in the disease.
The «typical» canine lymphoma patient is a middle aged dog presented to the veterinarian because one or more lumps have been found.
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor - specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.
A study to identify a predictive gene signature in the follicular lymphoma patients treated with pidilizumab in the current trial to facilitate identification of patients who are most likely to respond to the therapy.
Even lymphoma patients who were «bacteria - free» benefited from a three - week course of doxycycline therapy, and showed complete remission of the disease.
Improving Future Care for Lymphoma Patients SAGE invites you and your dog to participate in our long - term research study with ImpriMed, a Palo Alto - based company that creates personalized drug combinations to combat cancer and infectious diseases.
High serum vascular endothelial growth factor level is an adverse prognostic factor for high - risk diffuse large B - cell lymphoma patients treated with dose - dense chemoimmunotherapy.
Five - year survival data published online in Blood, the Journal of the American Society of Hematology (ASH), suggest that the targeted therapy brentuximab vedotin may have cured some Hodgkin lymphoma patients whose disease has persisted despite receiving previous therapies.
To block this signal, recent clinical studies have focused on inhibiting the activation of the B - cell receptor as a treatment for non-Hodgkin lymphoma patients, but with variable success.
While toxicity during induction is still of concern, especially in the elderly patients, we conclude from these data that de-escalation of induction therapy in elderly primary central nervous system lymphoma patients followed by maintenance treatment seems to be a promising treatment strategy.
But he also mentions a particular 20 - year - old lymphoma patient whose cancer had failed to respond to multiple chemotherapies.
In EBV lymphoma patients, however, things take a sinister turn.
Newly identified Hodgkin lymphoma patients enjoy a cure rate of more than 80 percent, but the chest radiation and chemotherapy drugs called anthracyclines used in the cures leave the survivors at an increased risk for multiple, life - long cardiovascular problems and premature death.
«Because Hodgkin lymphoma patients commonly receive treatment in their 20s and 30s, many of the stomach cancers arise before age 50, nearly 20 years earlier than is typical for newly diagnosed patients who have never had cancer.
Moreover, approximately 30 % of follicular lymphoma patients lose also a portion of chromosome 6, affecting multiple genes involved in suppressing the emergence of a tumor.
Beilhack and colleagues found that a slightly modified version of STAR2 has a similar effect on human T reg cells, suggesting that the approach could also prevent GvHD in leukemia and lymphoma patients after bone marrow or hematopoietic stem cell transplants.
Larsen will present the study, «Short and Long - Term Risk of Congestive Heart Failure in Breast Cancer and Lymphoma Patients Compared to Controls: an Epidemiologic Study,» on Saturday, March 10.
The Nordic Lymphoma Group has conducted a phase ll trial in newly diagnosed primary central nervous system lymphoma patients applying an age - adjusted multi-agent immunochemotherapy regimen, which in elderly patients included temozolomide maintenance treatment.
Data from 29 patients from the single - arm trial in relapsed follicular lymphoma patients showed a 66 % (19 patients) overall response rate — 15 patients were complete responses and 4 patients were partial responses.
The combination of rituximab and the novel immunotherapy pidilizumab (CT - 011) is both active and well tolerated in follicular lymphoma patients according to results of a phase II trial presented at ASH.
High Response Rate Among Lymphoma Patients and Promising Early Results in Trials for Pancreatic Cancer and Multiple Myeloma
Thirty - six percent of over 100 very ill lymphoma patients appeared disease - free six months after a single treatment, according to results released by the treatment's maker, Kite Pharma of Santa Monica, Calif..
When lymphoma patients are «staged» (see above under «does my pet need further tests»), stages are subcategorized as «a» or «b» depending on whether or not the patient is actually feeling ill or not.
Our current methods of generating the CD40 - B vaccine from lymphoma patients are laborintensive and require specialized laboratory equipment that is not available in most facilities.
This page features information on lymphoma and immunotherapy clinical trials for lymphoma patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based treatments to both children and adults with lymphoma.
Non-Hodgkin lymphoma patients are usually treated with rituximab (Rituxan ®, a monoclonal antibody) in combination with chemotherapy.
Exon - Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B - Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.
[3,4] Despite these advances, the late toxicities of chemotherapy and increased risk of secondary malignancies with RT have threatened the survival rates and quality of life of Hodgkin lymphoma patients.
B cell suppression in newborn following treatment of pregnant diffuse large B - cell lymphoma patient with rituximab containing regimen.
The combination of rituximab (Rituxan) and the novel immunotherapy pidilizumab (CT - 011) is both active and well tolerated in follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson Cancer Center in Houston, at the American Society of Hematology (ASH) meeting in Atlanta.
To demonstrate the technique's effectiveness, the researchers mapped genetic translocations present in lymph node biopsies of lymphoma patients.
Experience with lymphoma patients, who receive a transplant of their own blood or bone cells after radiation to wipe out their cancer, has shown «there's no doubt it helps,» says bone marrow transplant expert Nelson Chao of Duke University in Durham, North Carolina.
Pediatric Hodgkin lymphoma patients are among the possible beneficiaries.
Picking the right patients Despite the successes of these tailored immunological attacks on follicular lymphoma, not every lymphoma patient is likely to be a good match for the treatment.
The approach, which is described in a paper to be published September 7 in The Journal of Experimental Medicine, could allow those in need of such transplants, including leukemia and lymphoma patients, to be treated with fewer donor stem cells while limiting potential adverse side effects.
The lab of Elisa Oricchio at EPFL, with colleagues from the US and Canada, analyzed the genomes of over 200 follicular lymphoma patients.
Scientists in Germany have developed a new approach that may prevent leukemia and lymphoma patients from developing graft - versus - host disease (GvHD) after therapeutic bone marrow transplants.
Researchers tracked heart failure cases in 1,550 people without cancer and in 900 breast cancer and lymphoma patients in Olmsted County, Minnesota, from 1985 to 2010.
Notable among these are the use of BV prior to autologous stem cell transplant in Hodgkin lymphoma patients, to treat additional CD30 - positive lymphomas, and in patients with relapsed or treatment - resistant non-Hodgkin lymphoma.
Dose - densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high - risk diffuse large B - cell / follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study.
Exon Based Transcriptome Profiling Reveals Genes That Have Prognostic Impact on the Survival of Young High Risk Diffuse Large B Cell / Follicular Grade 3 Lymphoma Patients Treated with Dose - Dense Chemoimmuno - therapy and CNS Prophylaxis.
Currently, we are investigating CAR T cell therapy as a bridge to bone marrow transplant for leukemia and lymphoma patients and are unique in our research of CAR T in combination with transplant.
The ride also supports a study to determine whether magnesium supplements can boost leukemia and lymphoma patients» immune systems.
The combination improved upon the 40 % overall response rate seen for monotherapy rituximab treatment in relapsed follicular lymphoma patients.
He and his colleagues next plan to develop a clinical trial using the procedure for Hodgkin's and non-Hodgkin's lymphoma patients.
[2] The concept of combined - modality treatment was advanced by Dr. Kaplan and Dr. Saul Rosenberg, who demonstrated that extended - field RT and combination chemotherapy could be curative for Hodgkin lymphoma patients.